Capecitabine

SKU: orb1308702

Description

Capecitabine is an orally administered antimetabolite prodrug that is enzymatically converted to 5-fluorouracil (5-FU) within tumor cells. Its active metabolites, FdUMP and FUTP, inhibit DNA and RNA synthesis, respectively, making it a key tool for in vitro and in vivo cancer research, particularly in studies of colorectal, breast, and gastric malignancies.

Research Area

Cell Biology, Molecular Biology

Key Properties

• CAS Number: 154361-50-9
• MW: 359.35
• Purity: 100.00%
• Formula: C₁₅H₂₂FN₃O₆
• SMILES: O[C@H]1[C@@H](O[C@H](C)[C@H]1O)N2C(=O)N=C(NC(OCCCCC)=O)C(F)=C2
• Target: Nucleoside Antimetabolite/Analog,DNA/RNA Synthesis,Apoptosis
• Solubility: 5% DMSO+95% Saline:1.8 mg/mL (5.01 mM);PBS:50 mg/mL (139.14 mM);Ethanol:35.9 mg/mL (99.9 mM);DMSO:242 mg/mL (673.44 mM)

Bioactivity

• In Vivo:
  Capecitabine induces apoptosis in a Fas-dependent manner and exhibits toxicity sevenfold higher towards LS174T-c2 cells, which are transfected with thymidine phosphorylase, leading to more pronounced apoptosis. When cultured in the same plate as HepG2 cells, both LS174TWT and LS174T-c2 cells show increased sensitivity to Capecitabine, with IC50 values decreasing from 890 μM when LS174TWT cells are cultured alone to 630 μM when co-cultured with HepG2 cells. Additionally, for the LS174T-C2 subtype co-cultured with HepG2 cells, the IC50 significantly drops from 330±4 μM to 89±6 μM.
• In Vitro:
  When administered to mice with a high propensity for liver metastasis, Capecitabine exhibits inhibitory effects on both the growth and metastatic recurrence of human hepatocellular carcinoma. This phenomenon is attributed to the high expression of platelet-driven endothelial growth factor within the tumors. Compared to 5-FU, UFT, and the intermediate metabolite 5'-DFUR, Capecitabine demonstrates a broader spectrum of anticancer activity against human transplant tumors, which is associated with the tumor levels of dThdPase.
• Cell Research:
  HepG2 and either LS174T WT or LS174T-c2 cells are seeded, respectively, in the top and bottom chambers of 8-well strip membranes in 96-well plates. The exponentially growing cells are exposed to increasing concentrations of capecitabine. The medium is supplemented with 750 ng/mL ZB4 MoAB or 100 ng/mL BR17 MoAB when the latter are used in the experiments. After 72 hours of continuous exposure, LS174T viability is assessed using the classic colorimetric MTT test.(Only for Reference)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

DNASynthesis, DNA Synthesis, DNA/RNA Synthesis, Analog, Apoptosis, Capecitabine, Capecitibine, Capiibine, inhibit, NucleosideAntimetabolite, Nucleoside Antimetabolite/Analog, Nucleoside Antimetabolite, Inhibitor, Thymidine phosphorylase, Xeloda, RNASynthesis, RO 09-1978, RNA Synthesis

Compound Identifiers

PubChem CID

60953